Moody's Total Cost of Revenue increased by 6.0% to $531.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.1%, from $491.00M to $531.00M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 4.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $365.00M | $394.00M | $485.00M | $417.00M | $393.00M | $393.00M | $410.00M | $428.00M | $426.00M | $412.00M | $421.00M | $467.00M | $469.00M | $512.00M | $497.00M | $491.00M | $489.00M | $492.00M | $501.00M | $531.00M |
| QoQ Change | — | +7.9% | +23.1% | -14.0% | -5.8% | +0.0% | +4.3% | +4.4% | -0.5% | -3.3% | +2.2% | +10.9% | +0.4% | +9.2% | -2.9% | -1.2% | -0.4% | +0.6% | +1.8% | +6.0% |
| YoY Change | — | — | — | — | +7.7% | -0.3% | -15.5% | +2.6% | +8.4% | +4.8% | +2.7% | +9.1% | +10.1% | +24.3% | +18.1% | +5.1% | +4.3% | -3.9% | +0.8% | +8.1% |